targeted medication guide gene detection of breast cancer
buring rock breast core™, targeted at the patients with breast cancer, by applying the advanced second generation sequencing technology, can have a comprehensive detecting of drug-inhibited target genovariation related to breast cancer, provides comprehensive information for clinical individualized treatment, so as to realize the accurate treatment.
genes covered in breast core ™
targeted drugs covered in breast core™
more comprehensive individualized medication choice:
breast core™ comprehensively detects drug-inhibited target gene suggested in breast cancer nccn guideline, drugs-inhibit target spot researched in the clinical trial of breast cancer stage Ⅱ/Ⅲ and approved drug-inhibited target spot in all kinds of cancers, provides the most comprehensive individualized medication genetic detecting of breast cancer;
more accurate gene mutation detection related to lung cancer:
the gene detection panel based on the second generation sequencing technology optimized by burning rock dx, can detect 4 types of variation types at one time (mutation, insertion and deletion, fusion, amplification, etc.), at the same time, applies ultra deep sequencing to deeply cover trace genovariation, so as to provide full view of the precise genovariation although samples are limited. on the one hand, the parallel detecting with the polygenic high sensitivity improves the detection rate of drug-inhibited genovariation, which is able to miss opportunity of dedication; on the other hand, the complete coverage of exons can detect the hot spots and rare even unknown genovariation at the same time in one detection, detect related drug-resistant mutation while discovering drug sensitivity mutation(such as kras and alk point mutation), having an accurate reflection of the sensitivity and drug resistance information of the patients after the usage of medication.
more professional detection report interpretation:
buring rock dx, having the patented automated analysis system, is also the domestic third party detecting company only owning the professional medical department. the improved software and hardware resources ensures the accuracy of every detection report, which provides accurate and comprehensive basis of designing more reasonable individualized treatment scheme for doctors.
operation organization and biopsy samples, fresh tissues or paraffin embedding samples are available.
after sample inspection, detailed detection report will be issued in 10 natural days.